

AGENDA



POETIC Summer Meeting
February 28th – March 2nd, 2017
Lucile Packard Children's Hospital
Li Ka Shing Learning and Knowledge Conference Center
291 Campus Drive, Palo Alto, CA

Time	Session
Tuesday, February 28th	
4:00 - 5:00 PM PT (7:00 - 8:00 PM EST)	Board of Directors Meeting (Closed Meeting)
5:00 - 6:00 PM PT	PI Meeting (Closed Meeting)
6:00 PM PT	Dinner Closed to Board of Directors
Wednesday, March 1st	
POSTER SESSION: Throughout the meeting, posters from Young Investigators will be posted outside the session room for viewing. Select posters will be presented during the course of the meeting	
8:00 - 8:30 AM	Registration/Breakfast
	Greetings/Introductions <i>Norman Lacayo, MD</i> <i>Associate Professor</i>
	Welcome Address <i>Mary B. Leonard, MD, MSCE</i> <i>Professor and Chair, Department of Pediatrics</i> <i>Director, Child Health Research Institute</i> <i>Stanford University School of Medicine</i> <i>Adalyn Jay Physician-In-Chief</i>
	<i>Sheri Spunt MD, MBA</i> <i>Endowed Chair of Pediatric Cancer, Division Chief, Pediatric Hematology/Oncology, Co-Director, Bass Center for Childhood Cancer and Blood Diseases</i>
	<i>Tanya Trippett, MD</i> <i>Co-Founder and Director, POETIC</i>
8:30 - 8:45 AM	Roche Genentech Session Award Ceremony: 2017 Recipient of POETIC Partner of Distinction Award Update on Health Authorities Interactions Next Steps and Timelines for MATRIX Master Protocol <i>Gabi Lezcano, Operation Program Leader</i> <i>Erin Karski, MD, Associate Medical Director</i> <i>Natalie Young, Global Studies Leader</i> <i>YJ Choi, Statistician</i>
8:45- 10:45 AM	<i>Philip Eglinton, Global Category Manager, Academia</i>
10:45 -11:00 AM	Break
11:00 AM -12:00 PM	Invited Lecture: Stanford Lecture <i>Crystal Mackall, MD</i> <i>Director, Cancer Immunotherapy Program, Pediatric Oncology</i>

	<i>Lucile Packard Children's Hospital</i>
12:00 - 1:00 PM	Lunch (Presentation by Tree House Project Group)
Afternoon Session	
1:00 - 4:00 PM	POETIC Translational Genomics Session <i>POETIC Translational Genome Program</i> <i>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i> <i>Aru Narendran, MD, PhD, Alberta Children's Hospital</i>
1:00 - 1:30 PM	Comprehensive Testing of Molecular, Genomic and Immunologic Profiling in Pediatric Tumors - a POETIC Biology Study <i>Srikanth Ambati, MD, Memorial Sloan Kettering Cancer Center</i>
1:30 - 2:00 PM	Update from POETIC Preclinical Developmental Laboratory <i>Aru Narendran, MD, PhD, Alberta Children's Hospital</i>
2:00 - 2:30 PM	Update from POETIC Exosome Developmental Laboratory <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i>
2:30 - 2:40 PM	Break
2:40 - 3:10 PM	Update from Robert Arceci Epigenomics Program <i>DNA Program</i> <i>Bodour Salhia, PhD, University of Southern California</i>
3:10 - 3:40 PM	Update from Robert Arceci Epigenomics Program <i>RNA Program</i> <i>Olga Kovalchuk, MD, PhD, University of Lethbridge</i>
3:40 - 4:10 PM	POETIC Precision Biobank <i>Michael Roerhl, MD, Memorial Sloan Kettering Cancer Center</i>
4:10 - 5:00 PM	cBioPortal and Update from Center for Molecular Oncology <i>Nicholas Schultz, PhD, Memorial Sloan Kettering Cancer Center</i> <i>(CMO discussion to be presented by Nicholas Schultz)</i>
5:00 - 6:00 PM	Seattle Genetics Presentation – SGN33 Antibody Drug Conjugate <i>Phoenix Ho, MD, Associate Medical Director, Clinical Development</i>
6:00 PM	Meeting Adjourn and Travel to Hotel
7:00 PM	Dinner

Thursday, March 2nd	
7:30 - 8:00 AM	Registration/Breakfast
8:00 - 8:30 AM	PDX/Organoid Model Systems <i>Raj, Memorial Sloan Kettering Cancer Center</i>
8:30 - 9:00 AM	Preclinical and Clinical Development of PV-10 <i>Eric Wachter, PhD, Chief Technology Officer and Director, Provectus Biopharmaceuticals, Inc.</i> <i>Peter Culpepper, COO and Interim CEO, Provectus Biopharmaceuticals, Inc.</i>
9:00 - 9:30 AM	Preclinical and Clinical Development of Taurolidine NanoPro™ <i>Tony Pfaffle, MD, Chief Scientific Officer, Cormedix, Inc.</i> <i>Steve Laumas, MD, Advisor, NanoProteagen</i>
9:30 - 10:00 AM	Preclinical and Clinical Development of Mobitope <i>Scancell</i>

10:00 -10:15 AM	Break
10:15 – 11:00 AM	Notable Labs Presentation - Repurposing drug" testing platform
11:00 -11:30 AM	LOI: Phase I/II trial using Selinexor with Fludarabine and Cytarabine <i>Norman Lacayo, MD, Lucile Packard Children’s Hospital</i> <i>Jeffrey Rubinitz, MD, PhD, St. Jude Children’s Research Hospital</i> <i>Karyopharm</i>
11:30 – 12:00 PM	Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide <i>Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD</i>
12:00 -1:00 PM	Lunch (<i>Poster presentation</i>)
1:00 – 1:30 PM	Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session) <i>Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Sloan Kettering Cancer Center</i> <i>Anna Butturini, MD, PUMA Oncology</i> <i>Joseph DeStefano, Memorial Sloan Kettering Cancer Center</i>
1:30 -2:30 PM	Stanford Faculty Lecture
2:30 - 2:45 PM	Update from DCC <i>Joseph Destefano</i> <i>POETIC Research Program Director, POETIC DCC</i>
2:45 – 3:00 PM	Update from P2C2/Protocol Review Committee/ DCC <i>Cynthia Herzog, MD, MD Anderson Cancer Center</i> <i>Lisa McGregor, MD, Pennsylvania State Medical Center</i> <i>Joseph DeStefano, Memorial Sloan Kettering Cancer Center</i>
3:15- 4:00 PM	Outtake
4:00 PM	Adjourn